Injectable Diabetes Part 2.docx

29\. Which GLP-1 agonist has dual action as both a GLP-1 receptor agonist and a GIP receptor agonist? - A\) Liraglutide - B\) Semaglutide - C\) Dulaglutide - D\) Tirzepatide (Mounjaro®) Answer: D) Tirzepatide (Mounjaro®) 30\. What is the typical dosing schedule for long-acting insulin...

29\. Which GLP-1 agonist has dual action as both a GLP-1 receptor agonist and a GIP receptor agonist? - A\) Liraglutide - B\) Semaglutide - C\) Dulaglutide - D\) Tirzepatide (Mounjaro®) Answer: D) Tirzepatide (Mounjaro®) 30\. What is the typical dosing schedule for long-acting insulin such as insulin glargine? - A\) Once daily - B\) Twice daily - C\) Three times daily - D\) Before meals Answer: A) Once daily 31\. Which insulin product should not be mixed with other insulin products due to risk of inactivation? - A\) NPH insulin - B\) Regular insulin - C\) Insulin glargine - D\) Insulin lispro Answer: C) Insulin glargine 32\. What is the effect of insulin on adipose tissue? - A\) Reduces glucose uptake - B\) Increases triglyceride storage - C\) Promotes protein synthesis - D\) Reduces fatty acid uptake Answer: B) Increases triglyceride storage 33\. What is the onset time for regular insulin when administered subcutaneously? - A\) 10-15 minutes - B\) 30-60 minutes - C\) 1-2 hours - D\) 2-3 hours Answer: B) 30-60 minutes 34\. Which insulin type is recommended for use in insulin pumps? - A\) Insulin glargine - B\) Regular insulin - C\) Insulin aspart - D\) NPH insulin Answer: C) Insulin aspart 35\. Which insulin product has a milky appearance and must be rolled before administration? - A\) Regular insulin - B\) NPH insulin - C\) Insulin lispro - D\) Insulin glargine Answer: B) NPH insulin 36\. What is the primary benefit of using combination insulin products? - A\) Reduces the need for multiple injections - B\) Reduces hypoglycemia risk - C\) Increases blood glucose levels - D\) Promotes weight loss Answer: A) Reduces the need for multiple injections 37\. Which medication can be used as an alternative to mealtime insulin in patients with type 2 diabetes? - A\) GLP-1 agonists - B\) DPP-4 inhibitors - C\) SGLT2 inhibitors - D\) Sulfonylureas Answer: A) GLP-1 agonists 38\. What is the typical duration of action for rapid-acting insulin? - A\) 1-3 hours - B\) 3-5 hours - C\) 5-7 hours - D\) 7-9 hours Answer: B) 3-5 hours 39\. What is a key benefit of continuous subcutaneous insulin infusion (CSII) devices? - A\) Provides flexibility in daily scheduling - B\) Reduces the need for insulin - C\) Decreases the frequency of glucose monitoring - D\) Increases A1C levels Answer: A) Provides flexibility in daily scheduling 40\. Which insulin type is most commonly used in insulin pumps? - A\) Regular insulin - B\) NPH insulin - C\) Insulin aspart - D\) Insulin glargine Answer: C) Insulin aspart 41\. Which GLP-1 agonist is associated with the greatest reduction in weight? - A\) Dulaglutide - B\) Exenatide - C\) Semaglutide - D\) Liraglutide Answer: C) Semaglutide 42\. What is the maximum daily dose for insulin glargine pens? - A\) 50 units - B\) 60 units - C\) 70 units - D\) 80 units Answer: D) 80 units 43\. Which GLP-1 agonist has a once-weekly dosing schedule? - A\) Exenatide - B\) Liraglutide - C\) Dulaglutide - D\) Pramlintide Answer: C) Dulaglutide 44\. Which of the following insulin products can be used intravenously? - A\) Insulin glargine - B\) Insulin aspart - C\) Regular insulin - D\) Insulin lispro Answer: C) Regular insulin 45\. What is the benefit of using inhaled insulin (Afrezza®) in patients with diabetes? - A\) Avoids the need for injections - B\) Reduces hypoglycemia risk - C\) Increases insulin absorption - D\) Prolongs insulin action Answer: A) Avoids the need for injections 46\. What is the role of pramlintide (Symlin®) in diabetes management? - A\) Reduces hepatic glucose production - B\) Slows gastric emptying - C\) Increases insulin secretion - D\) Promotes glucagon release Answer: B) Slows gastric emptying 47\. What is the most significant adverse effect of insulin therapy? - A\) Weight gain - B\) Hypoglycemia - C\) Hyperglycemia - D\) Hypokalemia Answer: B) Hypoglycemia 48\. Which hormone released by the pancreas acts to raise blood glucose levels? - A\) Insulin - B\) Glucagon - C\) Amylin - D\) GLP-1 Answer: B) Glucagon 49\. What is a contraindication for inhaled insulin (Afrezza®)? - A\) Asthma - B\) Diabetes - C\) Renal failure - D\) Hepatic dysfunction Answer: A) Asthma 50\. What is the duration of action for NPH insulin? - A\) 4-6 hours - B\) 6-12 hours - C\) 12-24 hours - D\) 24-36 hours Answer: C) 12-24 hours 51\. Which GLP-1 agonist has the additional benefit of reducing cardiovascular events in patients with type 2 diabetes? - A\) Liraglutide - B\) Exenatide - C\) Dulaglutide - D\) Pramlintide Answer: A) Liraglutide 52\. Which of the following is an indication for insulin therapy? - A\) Type 1 diabetes - B\) Hypertension - C\) Hypokalemia - D\) Hyperlipidemia Answer: A) Type 1 diabetes 53\. What is the typical onset time for long-acting insulin such as insulin glargine? - A\) 30-60 minutes - B\) 1-2 hours - C\) 2-4 hours - D\) 4-6 hours Answer: C) 2-4 hours 54\. What is the benefit of combining insulin with GLP-1 agonists? - A\) Reduced insulin dose - B\) Increased weight gain - C\) Increased risk of hypoglycemia - D\) Increased glucagon secretion Answer: A) Reduced insulin dose 55\. Which hormone slows gastric emptying and promotes satiety? - A\) Insulin - B\) Glucagon - C\) GLP-1 - D\) Amylin Answer: C) GLP-1 56\. Which of the following is a contraindication for GLP-1 agonists? - A\) Gastroparesis - B\) Hyperglycemia - C\) Hypertension - D\) Hyperlipidemia Answer: A) Gastroparesis